Success Metrics

Clinical Success Rate
82.7%

Based on 43 completed trials

Completion Rate
83%(43/52)
Active Trials
7(9%)
Results Posted
40%(17 trials)
Terminated
9(12%)

Phase Distribution

Ph phase_1
6
8%
Ph phase_3
25
33%
Ph phase_4
4
5%
Ph not_applicable
6
8%
Ph phase_2
35
46%

Phase Distribution

6

Early Stage

35

Mid Stage

29

Late Stage

Phase Distribution76 total trials
Phase 1Safety & dosage
6(7.9%)
Phase 2Efficacy & side effects
35(46.1%)
Phase 3Large-scale testing
25(32.9%)
Phase 4Post-market surveillance
4(5.3%)
N/ANon-phased studies
6(7.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.4%

43 of 57 finished

Non-Completion Rate

24.6%

14 ended early

Currently Active

7

trials recruiting

Total Trials

76

all time

Status Distribution
Active(8)
Completed(43)
Terminated(14)
Other(11)

Detailed Status

Completed43
unknown11
Terminated9
Recruiting7
Withdrawn5
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
76
Active
7
Success Rate
82.7%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (7.9%)
Phase 235 (46.1%)
Phase 325 (32.9%)
Phase 44 (5.3%)
N/A6 (7.9%)

Trials by Status

completed4357%
terminated912%
unknown1114%
not_yet_recruiting11%
recruiting79%
withdrawn57%

Recent Activity

Clinical Trials (76)

Showing 20 of 76 trialsScroll for more
NCT05041907Phase 2

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Recruiting
NCT06600711Phase 3

Nitazoxanide for Treatment of Cryptosporidium in Children

Not Yet Recruiting
NCT04746183Phase 1

AGILE (Early Phase Platform Trial for COVID-19)

Recruiting
NCT07086937Not Applicable

Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children

Completed
NCT06993974Phase 2

Nitazoxanide in Patients With Ulcerative Colitis

Recruiting
NCT03395405Phase 2

NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

Completed
NCT04489381Phase 3

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Terminated
NCT05157269Phase 3

Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

Withdrawn
NCT05157243Phase 3

Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

Withdrawn
NCT04343248Phase 3

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Terminated
NCT04359680Phase 3

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

Completed
NCT04486313Phase 3

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

Completed
NCT02165813Phase 2

Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children

Terminated
NCT03905655Phase 2

Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

Completed
NCT04103216Not Applicable

Treatment of Cryptosporidiosis

Completed
NCT01227421Phase 2

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Completed
NCT06049901Phase 3

Nitazoxanide in Patients With Metastatic Colorectal Cancer

Recruiting
NCT05680792Not Applicable

Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers

Completed
NCT06010992Phase 2

Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus

Unknown
NCT04918927Phase 2

Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

Completed

Drug Details

Intervention Type
DRUG
Total Trials
76